Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform

NEXT STORY
Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
PREV STORY
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Novavax, Inc. of Class Action Lawsuit and Upcoming Deadline – NVAX
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

BOSTON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused ...

author_avatar
NASDAQ Market News

Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

SOUTH SAN FRANCISCO, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), ...

author_avatar
NASDAQ Market News

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible ...

author_avatar
NASDAQ Market News